Laurus Labs gets 1 USFDA observation for Visakhapatnam facility

Published On 2022-10-29 10:02 GMT   |   Update On 2022-10-29 10:02 GMT
Advertisement

Hyderabad: Laurus Labs today announced that the US Food and Drug Administration (USFDA) has concluded a PreApproval Inspection (PAI) with one observation at its manufacturing facility at Unit-5, Parawada, Visakhapatnam, Andhra Pradesh.

The inspection was conducted from 24th October 2022 to 28th October 2022.

"We have been issued a Form 483 with one observation. The observation is procedural in nature," the company stated in a BSE filing.

Advertisement

An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts. 

"The Company will address the observation within stipulated timelines," Laurus Labs said.

Read also: Laurus Labs inks pact with MPP to manufacture molnupiravir

Laurus Labs is an Indian pharmaceutical company headquartered in Hyderabad. The Company's major focus areas include anti-retroviral, Hepatitis C, and Oncology drugs.

Most of the Laurus Labs manufacturing facilities are approved by major regulatory authorities USFDA, WHO-Geneva, UK-MHRA, etc. 

Read also: Laurus gets CDSCO panel nod to market anti retroviral FDC Tenofovir Alafenamide Fumarate,Lamivudine, Dolutegravir

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News